Clinical trial
A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)
NCT00067743 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00067743 |
|---|---|
| Title | A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) |
| Official title | A Multicenter, Open-Label Study to Evaluate the Preliminary Safety and Efficacy of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) |
| Acronym | CRPS |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Complex Regional Pain Syndrome (RSD) |
| Intervention type | Drug |
| Interventions | Lenalidomide |
| Enrollment | 40 |
| Start date | Aug 1, 2003 |
| Primary completion | Oct 1, 2004 |
| Completion | Aug 1, 2007 |
| First posted | Aug 27, 2003 |
| Last update posted | Jan 3, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: